LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Qiagen Launches Portfolio of Environmentally Friendly Nucleic Acid Extraction Kits

By LabMedica International staff writers
Posted on 21 Jan 2022
Print article
Image: QIAGEN\'s new QIAwave products (Photo courtesy of QIAGEN N.V.)
Image: QIAGEN\'s new QIAwave products (Photo courtesy of QIAGEN N.V.)

QIAGEN N.V. (Venlo, Netherlands) has launched its new QIAwave product line of three nucleic acid extraction kits that use fewer components and produce less waste than existing ones. They are the first of their type to use both recycled plastics and space-saving chemical concentrates.

The QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit use up to 63% less plastic and up to 42% less cardboard than QIAGEN’s most popular kits for extracting DNA, RNA and plasmid DNA from samples. That makes them a more sustainable alternative to existing products – a major step in reducing the environmental impact of QIAGEN’s overall portfolio.

The new QIAwave products feature fewer components, waste tubes made from 100% recycled plastic, and suitable buffer concentrates in smaller bottles, rather than ready-to-go mixes. More compact kits and new ways of packing them reduce the amount of cardboard needed to box them up.

“QIAwave products are designed in collaboration with our customers to tackle the persistent problem of laboratory waste faced by scientists all over the world,” said Thomas Schweins, Senior Vice President, Head of Life Sciences. “These three kits are the first in a wave of continuous improvements and product evolutions that will reduce the environmental footprint of our products, while still delivering the same QIAGEN quality.”

Related Links:
QIAGEN N.V. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more